We are live on
!
Find out more
CC
Callan Capital Portfolio holdings
AUM
$1.35B
1-Year Est. Return
8.35%
This Fund
S&P 500
This Quarter
Est. Return
+6.01%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$243M
AUM Growth
-$2.1M
(-0.86%)
Cap. Flow
-$15.4M
Cap. Flow
% of AUM
-6.33%
Top 10 Holdings %
Top 10 Hldgs %
78.49%
Holding
71
New
3
Increased
8
Reduced
27
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$701K |
| 2 |
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
|
+$572K |
| 3 |
ALR
Alere Inc
ALR
|
+$290K |
| 4 |
iShares Russell 1000 ETF
IWB
|
+$251K |
| 5 |
Schwab Fundamental US Broad Market Index ETF
FNDB
|
+$230K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ImmunityBio
IBRX
|
+$2.66M |
| 2 |
Becton Dickinson
BDX
|
+$2.16M |
| 3 |
Alexandria Real Estate Equities
ARE
|
+$1.15M |
| 4 |
ResMed
RMD
|
+$1.02M |
| 5 |
Biogen
BIIB
|
+$881K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 88.95% |
| 2 | Healthcare | 11.05% |
| 3 | Consumer Discretionary | 0% |
| 4 | Consumer Staples | 0% |
| 5 | Financials | 0% |
Similar funds
MBA
SIA
AP
MW
SBIA
LC
TW
PAME
Callan Capital's Q3 2016 Portfolio in Review
As of Q3 2016, Callan Capital held 71 positions worth $243M, down 0.86% from $245M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Callan Capital withdrew a net $15.4M in Q3 2016, closing 26 positions and reducing 27 holdings. Its most notable exit was Becton Dickinson, an estimated $2.16M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 86% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Callan Capital opened a new position in Alere Inc worth $307K.
- Callan Capital's largest Q3 2016 buy was Alere Inc: 7,100 shares worth $307K.
- Callan Capital added most to Vanguard FTSE All-World ex-US ETF in Q3 2016, an estimated $701K increase.
- Callan Capital's biggest Q3 2016 reduction was ImmunityBio, cutting an estimated $2.66M.
- Callan Capital fully exited Becton Dickinson in Q3 2016, selling an estimated $2.16M.
- Callan Capital's ten largest holdings make up 78% of its $243M portfolio in Q3 2016.
- Callan Capital opened 3 new positions and closed 26 in Q3 2016.
- Callan Capital's portfolio value fell 0.86% quarter-over-quarter to $243M.
Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.